ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

OGN vs XENE // NET PROFIT MARGIN

Organon & Co. (NYSE) VS. Xenon Pharmaceuticals Inc. (NASDAQ) • 15-METRIC TALLY: OGN 8 — XENE 1
▲ NET PROFIT MARGIN LEADER: OGN
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (OGN VS. XENE) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC OGN XENE SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin 53.30% — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) 24.90% -35.00% +59.90 OGN /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield 14.83% -7.70% +22.53 OGN /fcf-yield <GO>
Operating Margin — -36.70% — TIE /operating-margins <GO>
Net Profit Margin ACTIVE 3.00% -34.00% +37.00 OGN /net-margins <GO>
Revenue Growth (YoY) -2.90% 7.70% -10.60 XENE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 2.43% 0.00% +2.43 OGN /dividend-safety <GO>
Altman Z-Score & Debt/Equity — 26.00 — TIE /balance-sheet <GO>
Piotroski F-Score Quality 6/9 5/9 +1.00 OGN /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 64.5 44.3 +20.20 OGN /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — 1.10 — TIE /macro-sensitivity <GO>
Forward P/E Multiple 18.0x 29.0x -11.00 OGN /forward-pe <GO>
Enterprise Scale & Market Cap $3.63B $3.62B $11.7M OGN /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR OGN REV XENE REV OGN GROSS % XENE GROSS % OGN FCF XENE FCF
FY 2025 $6.22B $1.04B 53.3% — $538.0M -$279.9M
FY 2024 $6.40B $782.0M 58.0% — $764.0M -$184.5M
FY 2023 $6.26B $599.4M — — $799.0M -$151.1M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
OGN // BETA —
XENE // BETA 1.10